Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 233 of 6351
-
New drug cocktail aims to extend life in Tough-to-Treat head and neck cancer
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuxima…
Phase 3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo could shrink tumors and reduce radiation side effects in nose cancer
Disease control Recruiting nowThis is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose ra…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
A nose spray before treatment: could naloxone speed up opioid recovery for fentanyl users?
Disease control OngoingThe opioid overdose epidemic has persisted for several decades and is now further complicated by the permeation of fentanyl into the illicit opioid supply. While the effectiveness of medications to treat opioid use disorder (MOUD) have been well documented in the literature, the …
Phase 3 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New combo attack: CAR T-Cells plus radiation takes on tough lymphoma
Disease control Recruiting nowTo learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could a new shot help toddlers breathe easier?
Disease control By invitation onlyThis is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, ran…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could online therapy plus ketamine rapidly curb suicidal thoughts?
Disease control Recruiting nowApproximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years). Most people with depression experience thoughts of suicide and many will also plan and/or attempt suicide at some time in the…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Can a radioactive tracer pinpoint Cancer's first stop?
Disease control CompletedThe aim of the study is a prospective multicentre phase-3 study that aims to evaluate the detection rate of sentinel lymph node in patients with breast cancer. To compare the detection rates of Technetium Tc 99m Sulfur Colloid Injection(99mTc-SC) and Mitoxantrone Hydrochloride I…
Phase 3 • Sponsor: HTA Co., Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New antibody combo aims to outsmart Hard-to-Treat lymphoma
Disease control Recruiting nowThis study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) that has come back …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
A smarter insulin that aims for the liver could curb dangerous nighttime dips
Disease control CompletedThe goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work …
Phase 2 • Sponsor: Diasome Pharmaceuticals • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread
Diagnosis Recruiting nowThe aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Phase 3 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Could waiting longer to clamp the cord boost outcomes for babies with heart defects?
Disease control Recruiting nowThe goal of this clinical trial is to compare 2 different timepoints for clamping the umbilical cord at birth for term-born infants with a prenatal diagnosis of congenital heart disease (CHD). The main questions it aims to answer are: * Does Delayed Cord Clamping at 120 seconds …
Sponsor: Carl Backes, MD • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingVitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in d…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Targeted Antibody-Drug combo aims to tackle High-Risk bladder cancer
Disease control OngoingThis is a prospective, open, single-center clinical study of the anti-HER2(Human epidermal growth factor receptor-2) ADC(antibody-drug conjugate) drug Disitamab Vedotin in combination with BCG(bacillus Calmette-Guerin) therapy in very high-risk NMIBC(Non-muscle invasive bladder c…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Blood test catches cancer early: new drug aims to stop spread
Disease control Recruiting nowThis is an international, multi-center, randomised, open label, superiority phase III trial of elacestrant vs standard endocrine therapy in patients with ER+/HER2- breast cancer and ctDNA relapse. During the ctDNA screening phase, patients will be tested at different timepoints …
Phase 3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could 5 radiation doses replace 45 for prostate cancer?
Disease control Recruiting nowThis phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipm…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New MS drug frexalimab faces off against standard treatment in major trial
Disease control OngoingThe purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of …
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New pill nemtabrutinib takes on standard blood cancer drugs in major trial
Disease control Recruiting nowThe goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new device suck out deadly lung clots?
Disease control CompletedEvaluation of the Safety and Efficacy of the Symphony Thrombectomy System in the Treatment of Pulmonary Embolism
Sponsor: Imperative Care, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail aims to put mantle cell lymphoma into deep remission
Disease control OngoingTrAVeRse is a multicentre, open-label, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at the end of AVR…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for tough prostate cancer: immunotherapy meets targeted radiation
Disease control OngoingIn this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Phase 1/2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC